midostaurin
novartis
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'midostaurin']
jtcc s james mccloskey, m.d., presented a study treating aml patients w/ flt3 mutations with cpx-351 and the flt3 inhibitor midostaurin. patients with flt3 mutations have very high risk aml. early data is promising. #ash2022 #aml #flt3
John Theurer Cancer Center @HackensackUMC is among the nation's top cancer hospitals with 14 specialized divisions providing the most advanced care possible.